Plymouth, United States
Endogenex, a Minneapolis-based company founded in 2017, is poised to transform diabetes care through pioneering medical innovations. With its strong partnership with the Mayo Clinic, the company is leveraging advanced technology to treat Type 2 Diabetes (T2D) by resetting the body's metabolic signaling systems, employing non-thermal pulsed electric fields.
The Endogenex System holds promise in improving metabolic functions, potentially enabling patients to better regulate blood glucose levels and mitigate disease progression, thus positioning Endogenex at the forefront of healthcare breakthroughs. Operating as a privately held clinical-stage company, Endogenex stands within the Health Care, Health and Wellness, and Medical Devices sectors.
The company recently secured an $88.00M Series C investment on June 25, 2024, backed by prominent investors such as Longitude Capital, Santé Ventures, Hatteras Venture Partners, Intuitive, Lumira Ventures, Mayo Clinic, and Orlando Health Ventures. This financial backing underscores strong market confidence in Endogenex's innovative approach to chronic disease management.
